Business Context and Reporting Period
This Form 8-K was filed by Autolus Therapeutics Plc on December 11, 2023, reporting events occurring on December 9, 2023. The filing serves as a Regulation FD disclosure regarding the company's participation in the American Society of Hematology (ASH) Annual Meeting held from December 9-12, 2023.
Key Financial Metrics
This filing is a current report focused on clinical data disclosures and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The material event reported is the dissemination of clinical data and pre-clinical results at the ASH Annual Meeting. Key updates include:
- FELIX Phase Ib/II Study: Oral presentation of pooled analysis data for obe-cel (an autologous fast off-rate CD19 CAR) in relapsed/refractory adult B-cell acute lymphoblastic leukemia (B-ALL).
- ALLCAR19 Phase I Study: Long-term update on obe-cel testing in adults with relapsed/refractory B-ALL, as well as patients with B-cell non-Hodgkin lymphoma (B-NHL) and B-cell chronic lymphocytic leukemia (B-CLL).
- AUTO8 Candidate: Presentation of pre-clinical and Phase I clinical data for AUTO8, a BCMA/CD19 co-targeting CAR T cell candidate for patients with refractory multiple myeloma.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, forward-looking projections, or a formal risk factor update. The primary focus is on the scientific progress of the company's pipeline. The company conducted an analyst and investor event on December 10, 2023, to discuss these updates. The press release and presentation materials are furnished as exhibits but are explicitly not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) and Exhibit 99.2 (ASH Corporate Presentation) for detailed clinical data tables and efficacy statistics.
- Verify the specific response rates and safety profiles for obe-cel in the FELIX and ALLCAR19 studies as presented at ASH.
- Assess the Phase I data for the AUTO8 BCMA/CD19 co-targeting candidate in refractory multiple myeloma.
- Check subsequent filings (e.g., 10-K or 10-Q) for the financial impact of ongoing clinical trials and cash burn rates, as this 8-K contains no financial data.